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DNA damage responseKP1019 comprises a class of ruthenium compounds having promising anticancer activity. Here, we
investigated the molecular targets of KP1019 using Saccharomyces cerevisiae as a model organism.
Our results revealed that in the absence of the N-terminal tail of histone H3, the growth inhibitory
effect of KP1019 was markedly enhanced. Furthermore, H3K56A or rtt109Dmutants exhibit hyper-
sensitivity for KP1019. Moreover, KP1019 evicts histones from the mononucleosome and interacts
speciﬁcally with histone H3. We have also shown that KP1019 treatment causes induction of
Ribonucleotide Reductase (RNR) genes and degradation of Sml1p. Our results also suggest that
DNA damage induced by KP1019 is primarily repaired through double-strand break repair (DSBR).
In summary, KP1019 targets histone proteins, with important consequences for DNA damage
responses and epigenetics.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
A major goal in clinical cancer research is to discover
compounds that can selectively inhibit the growth of cancer cells
without adversely affecting normal cell growth. A large number
of such compounds have been synthesized and tested for antican-
cer activity, and many of them are in clinical use. One of the most
widely used anti-cancer drugs is cisplatin. The pharmacological
activity of cisplatin was discovered by Rosenberg in 1969; later
on it became the ﬁrst inorganic anti-cancer drug introduced into
the clinics. Although cisplatin is successfully used against various
types of malignancies, its beneﬁts are limited due to resistance
developed by tumor cells [1–3]. Nevertheless, the success of
cisplatin indicates that metal compounds are a valuable option
for new chemotherapeutical approaches. Besides platinum, a wide
range of other metal compounds have been investigated for their
antitumor activity. Ruthenium compounds belong to the most
promising candidates of non-platinum metal complexes in cancer
therapy.
One of the most favorable among these complexes is KP1019
(FFC14A). KP1019 [indazolium trans-[tetrachlorobis(1H-inda-
zole)ruthenate(III)] is a metal complex which has been shown toact as cytostatic and cytotoxic drugs on colorectal tumor cells both
in vivo and in vitro [4–7]. This ruthenium compound is believed to
be a prodrug, which is activated to a more reactive ruthenium(II)
complex in the reducing environment of hypoxic regions that are
abundant in solid tumor tissues [8]. KP1019 shows activity against
a wide range of primary tumors by inducing apoptosis [9,10]. It has
been shown that KP1019 remains effective against cancer cell lines
that are highly resistant to other chemotherapeutic agents; adria-
mycin and doxorubicin [11]. The effect on cytosolic proteins upon
KP1019 treatment differs from that observed with cisplatin, sug-
gest that it exerts a speciﬁc mode of action which is different from
platinum drugs [10]. It is known that KP1019 reacts with human
serum proteins. The major fraction of the drug binds to albumin
or a smaller amount to transferrin [12,13]. As KP1019 binds to
transferrin receptors so it is hypothesized that it is internalized in-
side the cells through transferrin-dependent endocytosis but how
does it released from endosomes to cytosol is not clear. Recently
it has been shown that KP1019 induces DNA Damage, leading to
cell cycle delay and cell death in Saccharomyces cerevisiae [14].
Elucidation of the underlying mechanisms by which KP1019
inhibits cell growth will greatly help us to understand its applica-
tions in cancer therapeutics. Because mammalian cells are not well
suited for genetic screening approaches for pathway discovery, we
used genetically tractable model eukaryotes that might serve this
purpose. We elucidated the role of histone proteins, chromatin
modiﬁers and DNA repair proteins in response to KP1019 induced
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in higher eukaryotes including humans are targeted by this prom-
ising anticancer drug during treatment of cancer.
2. Materials and methods
2.1. Strains, chemicals, growth media and conditions
The S. cerevisiae strains used in this study are listed in
Supplementary Table 1. All chemicals, unless otherwise stated, used
in this study were purchased from Sigma. For supplementation of
iron and copper in the growth media ferrous sulfate heptahydrate
(FeSO47H2O) and Cuprous sulfate pentahydrate (CuSO45H2O)
were used respectively. For making synthetic complete (SC) media
all amino acids, yeast nitrogen base (YNB) and ammonium sulfate
were mixed together by following standard protocol as described
earlier [15]. All yeast strains used in this study were grown in SC
media at 30 C.
2.2. Synthesis of KP1019
KP1019 was synthesized following an established method [16].
RuCl33H2O was purchased from Sisco Research Laboratories, Inda-
zole was obtained from Sigma. The solvents used here were ob-
tained from Merck.
2.2.1. Puriﬁcation of RuCl33H2O
6 g of RuCl33H2O was dissolved in 38 ml of 12N HCl and 38 ml
of ethanol and reﬂuxed for 1 h. After cooling to 40 C, the ethanol
and produced acetaldehyde were removed by rotary evaporator.
The residues were ﬁltered and 38 ml of 12N HCl was added to
make a ﬁnal volume of 76 ml.
2.2.2. Synthesis of KP1019
4.5 g of Indazole was dissolved in 60 ml of 12N HCl and heated
to 70 C. 15 ml of Ru(III) solution was added to it and heated at
85 C for 15 min. An ochre-colored precipitate was observed and
stirring was continued till the hot solution cooled down to room
temperature. The resulting precipitate was separated out by ﬁltra-
tion. To remove HCl residues from the precipitate, the precipitate
was stirred with water for about 2 h. The resulting solid was ﬁl-
tered and subsequently washed with ethanol and diethylether
and dried under vacuum for 12 h.
We performed mass spectrometric analysis which veriﬁed the
identity of the synthesized compound as KP1019 shown in
Supplementary Fig. 1 (Figs. S1a and S1b). The spectra obtained
after mass spectrometric analysis of KP1019 were same as observed
earlier [17].
2.3. Preparation of mononucleosome and isolation of core histones
Intact nuclei were prepared from freshly excised chicken liver
tissue and core histones were prepared by hydroxyapatite chroma-
tography as described earlier [18]. The nuclear pellet was washed
with solution 3 containing 0.34 M sucrose in buffer A (15 mM
Tris–Cl; pH 7.5, 15 mM NaCl, 60 mM KCl, 0.5 mM spermidine,
0.15 mM spermine) with 15 mM b-ME and 0.2 mM PMSF. For
chromatin fractionation, nuclei were resuspended in the same buf-
fer containing 3 mM CaCl2 and were digested with 0.2 U of micro-
coccal nuclease (MNase) for 15 min at 37 C. Digestion was
terminated by adding 10 mM EDTA. Digested nuclei were centri-
fuged and supernatant (S1 fraction) was removed and the pellet
was resuspended in solution 3 containing 10 mM EDTA. After
10 min incubation on ice, the samples were centrifuged again to
collect supernatant (S2 fraction). S1 and S2 fractions were pooledand fractionated by Superose 6 size-exclusion column to purify
mononucleosomes.
2.4. Biochemical assay to investigate binding of KP1019 with
nucleosome and free histones
Mononucleosomes and free core histones were incubated sepa-
rately with increasing concentrations of KP1019 (0, 5, 10, 20,
50 lg/ml) and (0, 10, 20 lg/ml) respectively, at 37 C for 1 h. Trea-
ted and untreated mononucleosomes and core histones were elec-
trophoresed on 5% native-PAGE and 15% SDS–PAGE respectively.
Core histones were then immunoblotted with anti-H3 (Abcam,
1791) and anti-H4 antibody (Abcam, 15823).
2.5. Growth sensitivity and clonogenic cell survivability assay
To investigate the biological effect of KP1019 on the growth of
yeast cells, growth assay was carried out through spot tests as de-
scribed earlier [19,20] using serial dilutions of mid-log phase cul-
tures of wild-type and different mutant strains listed in
Supplementary Table 1. 3 ll volumes of serially diluted cultures
were spotted onto solid SCA plates containing DMSO (control) or
varying concentrations of KP1019 (25–100 lg/ml). All plates were
incubated at 30 C and growth of the yeast strains was recorded at
72 h by scanning the plates using a HP scanner. For growth curve
assay, exponentially growing yeast cells were treated with
KP1019 (10, 25, 50,100, 200 lg/ml) and optical density (OD600)
was measured at regular intervals for 6 h. Clonogenic assay was
carried as described earlier [15]. Equal number of mid-log phase
cells from untreated (DMSO) and KP1019 treated cultures (3 h)
were spread on SCA plates. The plates were incubated at 30 C
and after 36 h of incubation number of colonies were counted from
each plate. Experiments were done in triplicates and cell surviv-
ability was calculated with respect to untreated cells.
2.6. FACS analysis of yeast cells
Yeast cells in exponential phase were arrested in G1 phase by
treating them with alpha factor (Sigma) for 2 h as described previ-
ously [21]. Cells were released in SC media or SC supplemented
with KP1019 (25 lg/ml) and samples were taken out at regular
interval till 6 h. Cells were harvested and ethanol was added to cell
pellets, with vigorous vortexing. The cells were washed once with
50 mM sodium citrate buffer (pH 7.0). RNase A was added to the
samples and incubated at 37 C for 1 h. RNase A-treated samples
were transferred to BD FACS ﬂow containing 20 mg/ml propidium
iodide (Sigma). Cellular DNA was detected by a BD FACS Aria III
with BD FACS Diva software.
2.7. Confocal microscopy
To determine the effect of KP1019 on Sml1 and Rad52, Sml1-
YFP and Rad52-YFP yeast strains were imaged by confocal micros-
copy. A yeast colony was inoculated in 5 ml YPD, grown overnight
at 30 C. 200 ll of inoculate was transferred to fresh media and
cells were grown till exponential phase. KP1019 (25 lg/ml) was
added into culture media and treated for next 3 h. The cells were
then harvested, washed twice with PBS, and ﬁnally resuspended
in 200 ll PBS. The nuclear DNA was visualized with DAPI staining
to a ﬁnal concentration of 0.5 lg/ml. Confocal images were cap-
tured with LSM 780 confocal microscope (Carl zeiss, Germany)
by taking appropriate ﬁlter combinations for either YFP ﬂuores-
cence or DAPI. 63 oil immersion objective (Carl zeiss, Germany)
was used for visualizing yeast cells. Images were processed via
Zen 2010 software.
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zation MDA-MB-231 breast cancer cells were cultured as mono-
layer on the poly-L-lysine-coated coverslips. KP1019-treated (10,
20 and 50 lg/ml) cells were then ﬁxed. Nuclear staining of ﬁxed
cells was done with DAPI (Sigma).
2.8. Western blot analysis
Yeast mid-log phase cultures were treated with vehicle (DMSO)
or KP1019 (25–100 lg/ml) for 3 h and harvested. Whole cell pro-
tein extracts were obtained from the frozen yeast cell pellets by
20% trichloro-acetic acid (TCA) precipitation method followed by
immunoblotting analysis as described earlier [15,22]. Following
primary antibodies were used: General H3 (Sigma, H0164),
H3K4me1 (Abcam, 8895), H3K4me2 (Abcam, 32356), H3K9Ac (Ab-
cam, 69830), H3K9acS10P (Sigma, H9161), H3K18ac (Cell signal-
ing, 9675), H3K27ac (Abcam, 45173), H3K36me3 (Sigma,
SAB4800028), H3K56ac (Sigma, SAB4200328), H4K8ac (Abcam,
15823), Rnr1 (Agrisera, ASO9 576), Rnr2 (Agrisera, ASO9 575),
SmL1 (Agrisera, AS10847), Ubiquitin (Sigma, SAB4503053) and
polyclonal antibodies against recombinant TBP and RAP1 raised
in rabbit (Bhat Bio-tech, India (P) LTD).Fig. 1. KP1019 reduces yeast cell survivability in dose dependent manner. (A) Yeast satur
distilled water and 3 ll of each dilution was spotted on SCA plates containing DMSO (cont
in Section 2, Barr diagram showing cell survivability upon indicated concentration of KP1
Wild type yeast cells were grown in YPD medium till exponential phase then treated with
interval. Error bars represent the S.D. of three independent repeats. (D) Fluorescence ac
cycle. Wild type cells were released in SC medium (DMSO, control) or media containing 2
cultured cells were sampled and cellular DNA content was analyzed by FACS.3. Results
3.1. KP1019 inhibits S. cerevisiae cell growth in a dose dependent
manner and causes delay in cell cycle progression by arresting cells in
G2/M-phase
To investigate the effects of KP1019 on S. cerevisiae cell growth,
we performed drop plate assay with wild-type cells on synthetic
complete Agar medium (SCA) plates incorporated with increasing
concentration of KP1019 (25, 50, 100 lg/ml). 3 ll of 10-fold seri-
ally diluted over-night saturated cultures were spotted. The plates
were then incubated for 3 days at 30 C to allow the growth of
cells. Signiﬁcant growth inhibition was observed with increasing
dose of drug (Fig. 1A). These results show that KP1019 has inhibi-
tory effects on S. cerevisiae cell growth. To determine the concen-
tration of KP1019 required for growth inhibition, liquid cultures
of S. cerevisiae cells were incubated in synthetic complete (SC)
media containing concentrations of KP1019 ranging from 10 to
200 lg/ml. Cell growth was slightly inhibited by 25 lg/ml
KP1019 and inhibition was found more at 200 lg/ml of the drug
(Fig. 1B). To determine whether KP1019 causes cell death or its ef-
fect is reversible on cell growth, exponentially growing cells wereated cultures were serially diluted (101, 102, 103, 104) in 1.0 ml of sterile double
rol) or KP1019 (25, 50, 100 lg/ml). (B) Clonogenic assay was performed as described
019 treatment for 3 h. Error bars represent the S.D. of three independent repeats (C)
KP1019 (10–200 lg/ml) for 6 h. Growth was recorded by taking aliquots at regular
tivated cell sorting (FACS) analysis, showing the effect of the KP1019 on yeast cell
5 lg/ml KP1019. Cells were harvested at regular intervals as indicated in ﬁgure. The
V. Singh et al. / FEBS Letters 588 (2014) 1044–1052 1047incubated in SC media containing increasing concentrations of
drug (10–200 lg/ml) for 3 h. After drug treatment, the cells were
washed with drug-free medium, diluted, and then plated onto
SCA plates to determine the frequency of viable cells by colony for-
mation assay. Our result showed that there was signiﬁcant de-
crease in number of colonies upon treatment with KP1019
compared to untreated samples (Fig. 1C). Based on above men-
tioned experiments, we observed that the growth rate of yeast cells
was reduced upon KP1019 treatment, indicating that the drug is
possibly causing defects in cell cycle progression. To validate this
hypothesis, we performed FACS analysis to observe the cell cycle
progression in the presence and absence of KP1019. Exponentially
growing yeast cells were arrested in G1 phase as described in Sec-
tion 2. Cells were released in DMSO (control) or KP1019 (25 lg/ml)
for 6 h and samples were harvested at regular intervals as shown in
Fig. 1D. Cells were processed for FACS analysis. We observed accu-
mulation of yeast cells in the G2/M-phase (Fig. 1D) in response to
KP1019 treatment, indicating that the treatment inhibits the
movement of cells from the G2/M-phase, thus delaying the cell
cycle progression that is consistent with previously reported by
Stevens et al. [14]. All together, our results demonstrate that
KP1019 is inhibitory to S. cerevisiae cell growth even at very low
concentrations.
3.2. KP1019 evicts histones from soluble chromatin and interacts with
histone H3 in vitro
One of the ruthenium containing drug RAPTA-C has been shown
to interact with nucleosome core particle (NCP) by making histone
protein adducts [23]. We therefore made soluble chromatin asFig. 2. KP1019 evicts histones from mononucleosomal chromatin and interacts with hi
interaction with KP1019. (B) Mononucleosomal chromatin were treated with increasi
electrophoresis (PAGE) and stained with ethidium bromide (EtBr). Position of assembled
Core histones were incubated with KP1019 with indicated concentration for 1 h at 37 C.
analyzed by probing with histone H3 and H4 antibodies. Arrow indicate the appearancedescribed in Section 2 and gel ﬁltration chromatography was per-
formed to isolate the mononucleosomal fraction. Purity of mono-
nucleosome was assessed by agarose gel electrophoresis after
isolating DNA from mononucleosomal fraction (Fig. 2A). Mononu-
cleosome migrate slower than free DNA on native gels, as detected
by ethidium bromide staining (Fig 2B, lane1). Incubation of mono-
nucleosomes with increasing concentration of KP1019 leads to fas-
ter migration of mononucleosomal DNA indicating that it causes
release of histones from the DNA (Fig 2B, lane 2–5). This in vitro
system clearly demonstrated that the chemical nature of KP1019
alters structure of nucleosomes. Next we tested the interaction of
KP1019 with core histones. Upon treatment of core histones with
KP1019, we detected an appearance of slower migrating histone
H3 band by Western blotting (Fig. 2C, arrow) but we did not detect
any change in mobility of histone H4 acetylated at lysine 8 upon
KP1019 treatment suggesting that it causes release of histones
from the nucleosomal DNA by binding through the histone H3
not with acetylated H4 K8.
3.3. KP1019 targets histone proteins and chromatin modifying
enzymes without altering global histone modiﬁcations
Our in vitro results indicate that histone H3 is one of the poten-
tial targets of KP1019. To understand the physiological signiﬁcance
of this interaction we analyzed the effect of KP1019 on yeast cells.
Therefore, we employed various yeast histone tail mutants to
investigate the effect of KP1019. Removal of N-terminal tail of
H2A(1-20) or H3(1-30) leads to hypersensitivity to KP1019
(Fig. 3A) suggesting that these regions of histone tails are crucial
for providing resistance to this drug. Interestingly, we alsostone H3 in vitro. (A) Agarose-gel proﬁle of mononucleosomal chromatin used for
ng dose of KP1019 for 1 h. Samples were analyzed by native-polyacrylamide gel
nucleosomes (upper arrow head) and free DNA (lower arrow head) are indicated. (C)
Proteins were resolved by SDS–PAGE. The interaction of KP1019 and histones were
of high molecular weight band detected by H3 antibody.
Fig. 3. KP1019 targets histone proteins and its modifying enzymes. (A) Growth Assay; wild type and different mutant yeast strains were grown up to log phase. 3 ll of each
undiluted and 10-fold serially diluted culture was spotted onto control SCA (DMSO) plates or SCA plates containing 50 and 100 lg/ml KP1019. All plates were incubated at
30 C for 72 h and photographed. (B) Growth assays were performed with diploid strains as explained above. (C) Exponentially growing wild type (1588-4C) yeast cells were
treated with either DMSO or KP1019 (10–100 lg/ml) for 3 h. Whole cell extracts were prepared by TCA extraction method and samples were subjected to Western blot
analysis using indicated antibodies. Amount of Tbp and Ponceau S stained photograph of representative blot were used as loading controls.
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(H3K56A) in presence of KP1019. It is the established fact that
acetylation of H3K56 is required for DNA damage repair [24,25].
We also observed no or mild sensitivity of H3 point mutants
(H3PKR16-18A, H3QL19-20A, H3SK22-23A, H3RK26-27A,
H3SP28-30A, H3STG31-33A) towards KP1019. Upon multiple point
mutations (H3K4,9,14,18,23,27 to Q) as well as H4K5,8,12,16 to Q)
more severe growth defect was observed. Histone tails plays cru-
cial role in maintaining nucleosome structure [26,27]; the en-
hanced sensitivity showed by histone tail mutants for KP1019
suggest that KP1019 exhibits its effect by further destroying nucle-
osome structure in these mutants.
Based on our sensitivity assays, we concluded that KP1019
functions through histone proteins. Histone proteins are post-
translationaly modiﬁed by various chromatin modifying enzymes
which dictate the outcome of gene expression. Therefore, we
analyzed mutants of chromatin modifying enzymes for KP1019
sensitivity. We observed HDAC (rpd3D and sap30D) and HAT
(gcn5D, rtt109D, nut1D) knockout cells to be hypersensitive to
KP1019 (Fig. 3B). Cells with combinations of H4K-Q
(K5,8,12,16Q) point mutations and rpd3D deletion showed no ef-
fect of KP1019 on their growth (Fig. 3A). We also screened his-
tone methyl transferase (set2D, set3D, set4D, set5D, set6D, set7D
and dot1D) and histone demethylase (jdh1D and jdh2D) mutants
to examine the effect of KP1019 but did not observe any signiﬁ-
cant effect on their growth (Fig. 3B), indicating that KP1019 spe-
ciﬁcally activates signaling pathways which involves histone
acetylation. Next, we examined global changes in histone modiﬁ-
cations after KP1019 treatment in wild type yeast cells but failed
to detect any signiﬁcant alteration (Fig. 3C) suggesting that the
effect of KP1019 might be speciﬁc for localized region of chroma-
tin. Taken together, these results demonstrate that KP1019 medi-
ates its action through histone proteins and chromatin modifying
enzymes.Fig. 4. KP 1019 induces RNR gene expression through Mec1-Rad53-Dun1 checkpoint kin
spotted onto control SCA (DMSO) plates and SCA plates containing 25–100 lg/ml KP10
extracts were prepared by TCA extraction method and samples were subjected to Weste
were used as loading controls. (C) SmL1-YFP tagged strain were treated with KP1019 (25 l
taken as described in Section 2.3.4. KP1019 activates Mec1 Rad53 Dun1 checkpoint kinase pathway
leading to derepression of RNR genes
It is well established fact that H3K56 is acetylated during DNA
damage repair required for efﬁcient chromatin assembly [24,25].
Based on our sensitivity assay we observed hypersensitivity of
H3K56A mutant to KP1019. Hence we were motivated to elucidate
the reason behind it. The hallmark for DNA damage is the activation
of DNA damage response. The Mec1-Rad53-Dun1 checkpoint ki-
nase cascade is responsible for up-regulation of Ribonucleotide
Reductases (RNRs) in response to DNA damage and DNA replication
stress. Mec1-Rad53-dun1 kinases are activated upon DNA damage
leading to de-repression of RNR genes and degradation of SmL1
[28–30]. To understand the effect of KP1019 on DNA damage re-
sponse we analyzed the sensitivity of DNA damage checkpoint ki-
nase mutants. We observed drastic growth inhibition in upon
KP1019 treatments in absence of Mec1, Rad53, and Dun1 (Fig. 4A)
suggesting that KP1019 functions through DNA damage checkpoint
pathway. Next, we examined the protein expression of Rnr1 and
Rnr2 upon KP1019 treatment. We observed up-regulation of Rnr2
and degradation of SmL1 (Fig. 4B). Degradation of SmL1was further
conﬁrmed by confocal microscopy. We observed complete loss of
ﬂuorescence as compared to untreated cells upon treatments of
SmL1-YFP tagged cells with KP1019 for 3 h (Fig. 4C). MMS (0.03%)
treated cells were used as a positive control (Fig. 4C). All together,
these results indicate that KP1019 induce DNA damage response
by activation of Mec1-Rad53-Dun1 checkpoint kinase pathway
leading to up-regulation of RNRs and degradation of SmL1p.
3.5. KP1019 treatment primarily induces DNA single and double-
strand break repair pathway
To gain additional insight into the mechanism by which DNA
damage repair pathway is modulated upon KP1019 exposure, wease pathway. (A) Growth Assay; wild type and different mutant yeast strains were
19. All plates were incubated at 30 C for 72 h and photographed. (B) Whole cell
rn blot analysis with indicated antibodies. Tbp and Ponceau S of representative blot
g/ml) for 3 h. For control same strains were treated with MMS (0.03%), images were
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age repair pathways. We employed various yeast knockout mu-
tants defective in double-strand break repair (DSBR), Nucleotide
Excision Repair (NER) and Base Excision Repair (BER). We observed
mutants defective in single and double stranded DNA damage
repair pathways (rad5D, rad6D, rad9D, rad17D, rad18D, rad24D,
rad27D, rad50D, rad52D, rad54D, rad55D, rad57D, rad59D) to be
hypersensitive (Fig. 5A) while mutants involved in NER and BER
(rad2D, rad7D, rad16D, rad23D) were less sensitive to KP1019
(Fig. 5A, highlighted in red) as observed previously [14]. DSBs
can be repaired using different mechanisms [31–34] such as both
ends can be simply rejoined with little or no further processing
(non-homologous end joining, or NHEJ) or can be repaired using
homologous sequences (homologous recombination) [34]. In S.
cerevisiae, homologous recombination is the major pathway for
repairing DNA double-strand breaks. The key role played by
Rad52 in this pathway has been described by its ability to mediate
annealing of homologous DNA strands [35–39]. To further conﬁrm
that KP1019 leads to single or double strand DNA damage, we per-
formed confocal microscopy to observe Rad52 foci formation, a
marker for homologous recombination repair. We used Rad52-
YFP strain to visualize foci formation upon KP1019 treatment.
For positive control we treated cells with MMS (0.03%). We
detected Rad52 foci in control (MMS treated) as well as in
KP1019 treated cells (Fig. 5B and C) thereby further validating
our hypothesis that KP1019 induces DNA single and double-strand
break repair pathway and these results are consistent with
previously reported study by Stevens et al. [14].Fig. 5. Rad proteins provide resistance to KP1019. (A) Growth Assay; wild type and diff
plates containing 50 or 100 lg/ml KP1019. All plates were incubated at 30 C for 72 h a
KP1019 treatment. KP1019 treatment leads to generation of Rad52 foci, (B) Rad52-YFP
treated with 0.03% MMS (control) prior to visualization of foci by ﬂuorescence microscop
per repeat.4. Discussions
Metal compounds belong to the category of most important
chemotherapeutics for the treatment of human malignancies. In
addition to platinum-containing drugs, the ruthenium compound
KP1019 is one of the promising candidates in the development of
new cancer therapeutics [40]. Recently, KP1019 containing an
indazolium counterion demonstrated considerable anticancer
activity in a pilot clinical phase I study with minimum side effects
[40,41]. Despite of its potential role in cancer, mechanism of action
remains unclear. Use of KP1019 and its potential derivatives as
therapeutic agents for cancer treatment will beneﬁt from the elu-
cidation of the underlying mechanisms responsible for its anti-can-
cerous property.
Relative to platinum compounds, ruthenium antitumor agents
generally display lower reactivity towards double-stranded DNA.
KP1019 is thought to target mainly cytosolic proteins in the cell.
However, in nucleus, the chromatin (histone proteins and DNA)
are also potential therapeutic target of many drugs. One of the
ruthenium containing drugs RAPTA-C has been shown to interact
with nucleosome core particle (NCP) by making adducts with
histone proteins [23]. A similar kind of histone adduct has been ob-
served with acrolein [42]. Therefore, we were motivated to exam-
ine the interaction of KP1019 with histones. Interestingly, we
observed the appearance of a slow migrating band in SDS–PAGE
upon incubation of KP1019 with core histones which was identi-
ﬁed as histone H3 (Fig. 2C) suggesting that KP1019 behaves like
RAPTA-C. Similar kind of histone adduct has also been observederent deletion yeast strains were spotted onto control SCA (DMSO) plates and SCA
nd photographed. Red dotted box shows relatively lesser sensitive yeast strains for
tagged yeast strain was treated with KP1019 (25 lg/ml) for 3 h. Same strain was
y. Error bars represent the S.D. of three independent repeats; 200 cells were counted
Fig. 6. Proposed model showing molecular mode of action of KP1019 on Saccha-
romyces cerevisiae. After entering into yeast cells KP1019 targets epigenetic
machinery of the cells and our in vitro results suggests that KP1019 causes eviction
of histones from the chromatin. We also show that KP1019 causes activation of DNA
damage response leading to up-regulation of RNR genes and degradation of Sml1p.
Taken together, our results show that KP1019 functions through targeting multiple
cellular pathways in yeast and we propose that identical pathways might be
affected by this anti-cancer drug in higher eukaryotes.
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KP1019 with soluble chromatin (mononucleosome) leads to desta-
bilization of nucleosome (Fig. 2B). A similar phenomenon was ob-
served with doxorubicin which was shown to evict histones from
chromatin [43] suggesting that KP1019 and doxorubicin shares
common mode of action.
To understand the physiological signiﬁcance of the interaction
between histne and KP1019, we analyzed the effect of this drug
on histone tail mutants. We tested the sensitivity of single or dou-
ble point mutant in H3N-ter tail (PKR16-18A, QL19-20A, SK22-23A,
RK26-27A, and SP28-30A) but failed to observe any defect in their
growth. The single and double point mutants of H3N-terminal tail
were not sensitive to KP1019 (Fig. 3A), whereas H3D (1-30) and N-
terminal lysine to glutamate (H3K-Q) mutants were found hyper-
sensitive (Fig. 3A). It is well known that histones play important
role in replication and survival in the presence of genotoxic agents
[44–46]. Histone tail mutants are sensitive to genotoxic agents [46]
too. It is also known that cells lacking H3K56ac (H3K56A and
rtt109D) showed hypersensitive to genotoxic agents [24,25].
Rtt109 is involved in up-regulation of RNR3 transcript levels upon
genotoxic stress [47], the sensitivity conferred by rtt1019 mutant
for KP1019 also suggests that the lack of RNR3 expression in
RTT109 might be responsible for observed sensitivity. Acetylation
of H3K56 by Rtt109 is required for chromatin assembly during
DNA repair [48]. We observed H3K56A mutants and rtt109D cells
to be more sensitive to KP1019 treatment (Fig. 3A and B). Taken to-
gether, these results suggest that KP1019 induces DNA damage and
histone proteins play a central role in providing tolerance to
KP1019 induced stress. Considering the probable interaction with
histone H3, it is important to understand how KP1019 regulates
signaling that involves histone modiﬁcations.
Based on the sensitivity assays performed with histone tail mu-
tants, it is evident that KP1019 causes DNA damage which is con-
sistent with the earlier reports. For instance, a report says that it
triggers hydrogen peroxide production resulting into oxidative
stress and DNA damage [49]. In contrast, according to another
study it can damage DNA directly by making protein-DNA and
interstrand cross-links [50]. Moreover, KP1019 has been reported
to act as a topoisomerase II poison by forming a drug-containing
cleavage complex [51]. We observed that KP1019 treatment leads
to the activation of DNA damage response (Fig. 4A and B). We fur-
ther observed formation of Rad52 foci upon KP1019 treatment
(Fig. 5B and C) suggesting that it triggers DSBR. Interestingly, DSBR
mutants showed more sensitivity as compared to NER or BER mu-
tants (Fig. 5A) which further conﬁrms that KP1019 primarily in-
duces DNA single or double-strand break repair pathway.
Replication stress induced by diverse genotoxins is also known to
generate DSBs [52,53]. Our investigations with KP1019 suggest
that it too generates replication stress. This ﬁnding is also consis-
tent with an earlier report that KP1019 treatment results in DNA
breaks in HT29 colon carcinoma cells [49].
All together, we used yeast as a model system to explore the
mode of action of KP1019, and our results strongly suggest that
KP1019 inhibits eukaryotic cell growth by targeting multiple cellu-
lar pathways. Our present study sheds light on the mode of action
of KP1019 and demonstrates signiﬁcant similarities with doxorubi-
cin. Doxorubicin acts by evicting histones from chromatin [43] and
creates DNA breaks [54]. We observed similar mode of action with
KP1019. However, the applications of doxorubicin in oncology are
limited due its side effects, particularly cardio toxicity [55] and co-
lon cancer cells developed resistance [56,57]. Since KP1019 shares
similar property with doxorubicin, hence we propose that KP1019
can be an effective candidate for the treatment of doxorubicin
resistant cancerous cells.
In conclusion, our present ﬁnding can be summarized in a mod-
el depicting the proposed molecular mode of action of KP1019 in S.cerevisiae (Fig. 6). Our present studies have identiﬁed several po-
tential pathways affected by KP1019; including host epigenetics
and DNA damage response. The ﬁndings of this study demonstrate
that S. cerevisiae will serve an important role for the elucidation of
the underlying mechanisms of KP1019-induced cytotoxicity which
may be useful in clinical applications.
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